Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

nL-TARD-001

Personalized antisense oligonucleotide

Trial Locations (2)

Columbia University, Irving Medical Center, New York

Houston Methodist, Houston

All Listed Sponsors

collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Columbia University

OTHER

lead

n-Lorem Foundation

OTHER

NCT07095712 - Personalized Antisense Oligonucleotide Therapy for A Single Participant With TARDBP ALS | Biotech Hunter | Biotech Hunter